UPDATE: Morgan Stanley Cuts PT to $42 on MetLife Following Guidance
Morgan Stanley reiterated its Overweight rating on MetLife (NYSE: MET) but lowered its price target from $44 to $42.
Morgan Stanley noted, "MetLife's guidance was modestly disappointing, with both EPS and capital expectations running somewhat below our expectations. That said, their guidance is typically conservative (they typically hit at least the high end), and even with lowered numbers, the valuation multiple on stock is very low."
MetLife closed at $33.61 on Wednesday.
Latest Ratings for MET
|Mar 2017||Bank of America||Downgrades||Buy||Neutral|
|Jan 2017||Citigroup||Initiates Coverage On||Sell|
|Jan 2017||Deutsche Bank||Upgrades||Hold||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.